MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03188ntm a2200349 i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MY-KuUP |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20260421121423.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
t||||fr|||| 000 0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
ta |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
260421t20252025my a|||fr|||| 000 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
THE0010485 (Local) |
| Qualifying information |
Hardback |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
UMPSA |
| Language of cataloging |
eng |
| Transcribing agency |
UMPSA |
| Description conventions |
rda |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
FIST .S54 2025 r Bc. |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Shanjievan A/l Arivazhagan, |
| Relator term |
author. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Synthesis of 2-(3-methoxybenzoyl) cycl ohexan-1-one and exploration of their potential as antialzheimer agents through molecular docking studies / |
| Statement of responsibility, etc. |
Shanjievan A/l Arivazhagan |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Kuantan, Pahang : |
| Name of producer, publisher, distributor, manufacturer |
UMPSA, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2025 |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
© 2025 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xvii, 77 pages : |
| Other physical details |
illustrations ; |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| Source |
rda |
| File type |
text file |
| Encoding format |
PDF |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Faculty of Industrial Sciences and Technology |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Final Year Report (Bachelor of Applied Science of Industrial Chemistry) -- Universiti Malaysia Pahang Al-Sultan Abdullah - 2025 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Include bibliographical reference |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with neuronal death, cognitive decline, and amyloid plaques and neurofibrillary tangles. Treatments available today are limited to symptom management and are often accompanied by significant side effects, highlighting the need for safer and more effective therapeutic agents. In this study, 2-(3-methoxybenzoyl)cyclohexan-1-one was synthesized, characterized using FTIR and NMR, and evaluated for its potential as an anti-Alzheimer agent using molecular docking studies. The compound was made by enamine and acylation reactions, monitored with thin-layer chromatography (TLC), and purified with column chromatography, obtaining 0.3446 g of the product with a 14.9% yield. NMR spectroscopy confirmed 14 distinct carbon environments, and FTIR analysis confirmed diketone peaks at 1710.01 and 1677.84 cm⁻¹, validating the structure of the synthesized compound. Molecular docking studies were performed using SwissDock with the crystal structure of acetylcholinesterase (AChE, PDB ID: 4EY7). The synthesized compound showed a binding affinity of −6.503 kcal/mol, whereas the cocrystallized ligand and FDA-approved drug brexpiprazole displayed binding affinities of −7.261 kcal/mol and −7.962 kcal/mol, respectively. The synthesized compound had a lower binding affinity but exhibited four hydrophobic contacts with ALA397, ALA528, TYR382, and HIS381, and two π-stacking interactions with HIS381 and TYR382 in the AChE active site, suggesting its potential inhibitory activity. The research conducted demonstrates the promise of 2-(3-methoxybenzoyl)cyclohexan-1-one as a candidate AD therapeutic and the utility of combining synthetic chemistry and computational studies to identify and optimize novel therapeutic agents. |
| 610 20 - SUBJECT ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Faculty of Industrial Sciences and Technology |
| General subdivision |
Dissertations |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Universities and colleges |
| General subdivision |
Dissertations |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Theses |
| General subdivision |
Dissertations |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
https://umpir.ump.edu.my/id/eprint/46111 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Final Year Report |